Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation
Status:
Completed
Trial end date:
2018-01-02
Target enrollment:
Participant gender:
Summary
Functional MR is caused by adverse left ventricular remodeling after myocardial injury and
associated with an increased incidence of heart failure and death. Because secondary
functional MR usually develops as a result of LV dysfunction, diuretics, beta blockers,
angiotensin-converting-enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), and
aldosterone antagonists are given to patients with functional MR in line with the guidelines
in the management of heart failure. However, functional MR appears to remain common despite
use of these drugs and current medical treatment is usually insufficient for reducing MR or
reversing the adverse LV remodeling. As LCZ696 is a dual-acting inhibitor of the
renin-angiotensin-aldosterone system (RAAS) and neutral endopeptidase (NEP), LCZ696 has
greater hemodynamic and neurohormonal effects than ARB alone. Investigators try to examine
the hypothesis that LCZ696 is superior to ARB alone in improving functional MR in patients
with LV dysfunction and functional MR.
Phase:
Phase 4
Details
Lead Sponsor:
Asan Medical Center
Collaborator:
Novartis
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan